ESR1 and ovarian cancer: This discrepancy may reflect treatment differences, as BRCA2-mutant breast cancers are typically estrogen receptor-positive (ER +) and are treated with hormonal therapies rather than platinum-based agents or PARP inhibitors, which are standard first-line therapies in BRCA2-deficient ovarian cancer.